Triumph Capital Management Purchases 9,744 Shares of Pfizer Inc. (NYSE:PFE)

Triumph Capital Management raised its holdings in shares of Pfizer Inc. (NYSE:PFE) by 64.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 24,820 shares of the biopharmaceutical company’s stock after buying an additional 9,744 shares during the quarter. Triumph Capital Management’s holdings in Pfizer were worth $715,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in the business. Trifecta Capital Advisors LLC lifted its stake in Pfizer by 3.7% in the third quarter. Trifecta Capital Advisors LLC now owns 9,197 shares of the biopharmaceutical company’s stock worth $305,000 after purchasing an additional 325 shares during the last quarter. Confluence Wealth Services Inc. lifted its stake in shares of Pfizer by 0.5% during the 3rd quarter. Confluence Wealth Services Inc. now owns 65,053 shares of the biopharmaceutical company’s stock worth $2,158,000 after acquiring an additional 342 shares during the last quarter. Carr Financial Group Corp boosted its holdings in Pfizer by 3.3% during the 3rd quarter. Carr Financial Group Corp now owns 11,012 shares of the biopharmaceutical company’s stock valued at $344,000 after acquiring an additional 355 shares during the period. Caldwell Sutter Capital Inc. grew its position in Pfizer by 0.5% in the 3rd quarter. Caldwell Sutter Capital Inc. now owns 69,794 shares of the biopharmaceutical company’s stock valued at $2,315,000 after acquiring an additional 364 shares during the last quarter. Finally, Lafayette Investments Inc. lifted its position in shares of Pfizer by 2.2% during the third quarter. Lafayette Investments Inc. now owns 17,470 shares of the biopharmaceutical company’s stock worth $579,000 after purchasing an additional 368 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

PFE has been the topic of a number of research analyst reports. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a report on Monday, April 15th. Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Guggenheim initiated coverage on Pfizer in a report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price target for the company. Finally, TD Cowen lowered Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price for the company. in a research report on Thursday, January 4th. Eleven research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $36.33.

Pfizer Stock Up 6.0 %

Shares of PFE traded up $1.55 during mid-day trading on Wednesday, hitting $27.17. 55,744,603 shares of the company traded hands, compared to its average volume of 42,082,469. The business has a 50 day moving average of $26.88 and a 200 day moving average of $28.26. The company has a market capitalization of $153.85 billion, a PE ratio of 75.67, a price-to-earnings-growth ratio of 1.16 and a beta of 0.61. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69. Pfizer Inc. has a 1-year low of $25.20 and a 1-year high of $40.37.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, topping the consensus estimate of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The business had revenue of $14.25 billion during the quarter, compared to the consensus estimate of $14.37 billion. During the same period in the previous year, the firm posted $1.14 earnings per share. The business’s revenue for the quarter was down 41.3% compared to the same quarter last year. Equities research analysts anticipate that Pfizer Inc. will post 2.24 EPS for the current year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Friday, May 10th will be given a dividend of $0.42 per share. The ex-dividend date is Thursday, May 9th. This represents a $1.68 dividend on an annualized basis and a yield of 6.18%. Pfizer’s dividend payout ratio is currently 466.67%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.